|
Activating mitochondrial function and haemoglobin expression with EH-201, an inducer of erythropoietin in neuronal cells,reverses memory impairment.
Lin-Yea Horng, Pei-Lun Hsu, Li-Wen Chen, Wang-Zou Tseng, Kai-Tin Hsu, Chia-Ling Wu and Rong-Tsun Wu
British Journal of Pharmacology, 172: 4741, 2015.
CONCLUSIONS AND IMPLICATIONS: The induction of endogenous erythropoietin in neuronal cells by inducers such as EH-201 might be a therapeutic strategy for memory impairment in neurodegenerative disease, physiological ageing or traumatic brain injury.
|
|
|
|
|
|
Advantage of AH-501-NDD :
|
|
|
|
|
|
1.
|
Our publication in British of Pharmacology was chosen by World Biomedical Frontiers in section of Alzheimer because of its innovation and potential for significant impact. (Oct 27, 2015)
|
|
2.
|
There were over 1,200 clinical trials in Alzheimer’s disease failed so far.
|
|
3.
|
AH-501-NDD is an endogenous EPO inducer in neural cells and produced tissue specific factor NGF and BDNF for activating autophagy to remove the abnormal aggregate proteins in a cellular huntington’s model.
|
|
|
|
|
Global market for Neurodegenerative diseases
|
|
|
|
|
|
GBI Research 2016
The neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%.
|
|